Fernanda M Consolim-Colombo1,2, Carine T Sangaleti1,3, Fernando O Costa2, Tercio L Morais2, Heno F Lopes1,2, Josiane M Motta2, Maria C Irigoyen1, Luiz A Bortoloto1, Carlos Eduardo Rochitte1, Yael Tobi Harris4, Sanjaya K Satapathy5, Peder S Olofsson6,7, Meredith Akerman8, Sangeeta S Chavan6,9, Meggan MacKay10, Douglas P Barnaby11, Martin L Lesser8, Jesse Roth12, Kevin J Tracey6,9, Valentin A Pavlov6,9. 1. University of Sao Paulo, Hypertension Unit, Sao Paulo, Brazil. 2. Nove de Julho University (UNINOVE), PPG, Sao Paulo, Brazil. 3. Midwestern State University (UNICENTRO), Paraná, Brazil. 4. Hofstra Northwell School of Medicine at Hofstra University, Division of Endocrinology, Diabetes and Metabolism, Hempstead, New York, USA. 5. Methodist University Hospital, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA. 6. Center for Biomedical Science, and. 7. Center for Bioelectronic Medicine, Department of Medicine, Center for Molecular Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 8. Biostatistics Unit, and. 9. Center for Bioelectronic Medicine, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. 10. Center for Autoimmune & Musculoskeletal Disease, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA. 11. Department of Emergency Medicine of Albert Einstein College of Medicine, Bronx, New York, USA. 12. Laboratory of Diabetes and Diabetes-related Research, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA.
Abstract
BACKGROUND: Metabolic syndrome (MetS) is an obesity-driven condition of pandemic proportions that increases the risk of type 2 diabetes and cardiovascular disease. Pathophysiological mechanisms are poorly understood, though inflammation has been implicated in MetS pathogenesis. The aim of this study was to assess the effects of galantamine, a centrally acting acetylcholinesterase inhibitor with antiinflammatory properties, on markers of inflammation implicated in insulin resistance and cardiovascular risk, and other metabolic and cardiovascular indices in subjects with MetS. METHODS: In this randomized, double-blind, placebo-controlled trial, subjects with MetS (30 per group) receivedoral galantamine 8 mg daily for 4 weeks, followed by 16 mg daily for 8 weeks or placebo. The primary outcome was inflammation assessed through plasma levels of cytokines and adipokines associated with MetS. Secondary endpoints included body weight, fat tissue depots, plasma glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), cholesterol (total, HDL, LDL), triglycerides, BP, heart rate, and heart rate variability (HRV). RESULTS:Galantamine resulted in lower plasma levels of proinflammatory moleculesTNF (-2.57 pg/ml [95% CI -4.96 to -0.19]; P = 0.035) and leptin (-12.02 ng/ml [95% CI -17.71 to -6.33]; P < 0.0001), and higher levels of the antiinflammatory molecules adiponectin (2.71 μg/ml [95% CI 1.93 to 3.49]; P < 0.0001) and IL-10 (1.32 pg/ml, [95% CI 0.29 to 2.38]; P = 0.002) as compared with placebo. Galantamine also significantly lowered plasma insulin and HOMA-IR values, and altered HRV. CONCLUSION: Low-dose galantamine alleviates inflammation and insulin resistance in MetS subjects. These findings support further study of galantamine in MetS therapy. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT02283242. FUNDING: Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil, and the NIH.
RCT Entities:
BACKGROUND:Metabolic syndrome (MetS) is an obesity-driven condition of pandemic proportions that increases the risk of type 2 diabetes and cardiovascular disease. Pathophysiological mechanisms are poorly understood, though inflammation has been implicated in MetS pathogenesis. The aim of this study was to assess the effects of galantamine, a centrally acting acetylcholinesterase inhibitor with antiinflammatory properties, on markers of inflammation implicated in insulin resistance and cardiovascular risk, and other metabolic and cardiovascular indices in subjects with MetS. METHODS: In this randomized, double-blind, placebo-controlled trial, subjects with MetS (30 per group) received oral galantamine 8 mg daily for 4 weeks, followed by 16 mg daily for 8 weeks or placebo. The primary outcome was inflammation assessed through plasma levels of cytokines and adipokines associated with MetS. Secondary endpoints included body weight, fat tissue depots, plasma glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), cholesterol (total, HDL, LDL), triglycerides, BP, heart rate, and heart rate variability (HRV). RESULTS:Galantamine resulted in lower plasma levels of proinflammatory molecules TNF (-2.57 pg/ml [95% CI -4.96 to -0.19]; P = 0.035) and leptin (-12.02 ng/ml [95% CI -17.71 to -6.33]; P < 0.0001), and higher levels of the antiinflammatory molecules adiponectin (2.71 μg/ml [95% CI 1.93 to 3.49]; P < 0.0001) and IL-10 (1.32 pg/ml, [95% CI 0.29 to 2.38]; P = 0.002) as compared with placebo. Galantamine also significantly lowered plasma insulin and HOMA-IR values, and altered HRV. CONCLUSION: Low-dose galantamine alleviates inflammation and insulin resistance in MetS subjects. These findings support further study of galantamine in MetS therapy. TRIAL REGISTRATION: ClinicalTrials.gov, number NCT02283242. FUNDING: Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil, and the NIH.
Authors: Sol M Rodríguez-Colón; Fan He; Edward O Bixler; Julio Fernandez-Mendoza; Alexandros N Vgontzas; Susan Calhoun; Zhi-Jie Zheng; Duanping Liao Journal: Metabolism Date: 2015-02-03 Impact factor: 8.694
Authors: Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney Journal: Rev Endocr Metab Disord Date: 2020-08-26 Impact factor: 6.514
Authors: Pamela Nithzi Bricher Choque; Rodolfo P Vieira; Luis Ulloa; Caren Grabulosa; Maria Claudia Irigoyen; Katia De Angelis; Ana Paula Ligeiro De Oliveira; Kevin J Tracey; Valentin A Pavlov; Fernanda Marciano Consolim-Colombo Journal: Front Pharmacol Date: 2021-05-04 Impact factor: 5.810
Authors: Michael Eberhardson; Laura Tarnawski; Monica Centa; Peder S Olofsson Journal: Cold Spring Harb Perspect Med Date: 2020-03-02 Impact factor: 6.915